INCY

Incyte Corporation

HALAL

Score: 86/100

stock

Is INCY Halal?

Biopharmaceutical company focused on oncology and inflammation — permissible drug research with a strong, low-debt balance sheet.

What You Should Know

Incyte Corporation is a commercial-stage biopharmaceutical company that discovers, develops, and markets therapies in oncology, hematology, and inflammation and autoimmunity, anchored by its JAK-inhibitor franchise. Developing and selling medicines is a permissible activity, so the business-activity screen passes cleanly. Incyte is notable among biotechs for carrying very little debt and a large cash position, so the total-debt-to-market-cap screen is comfortably within the 33% threshold; still, confirm the debt and receivables ratios against the latest filings. The main purification item is interest income earned on the sizable cash and marketable-securities balance — this should be checked against the 5% threshold and the corresponding portion of returns purified. On that basis Incyte is generally screened as halal, with only routine purification of interest income.

⚠️ Concerns

•Earns interest income on a large cash and marketable-securities balance — check it against the 5% threshold and purify the corresponding portion of returns
•Confirm total debt / market cap against the 33% threshold and the receivables ratio against the board's threshold (49–70%) using the latest filings
•Revenue is concentrated in a small number of key products, so the business is exposed to patent and competitive risk — re-screen periodically
•The overall profile is clean, but ratios can shift as the company grows and adds products

🧾

Own INCY? Purify your portfolio.

Per-holding purification amounts, zakat on your shares, and halal alternatives for flagged holdings — a personalized report prepared for you within 48 hours.

Order Your Report — $49 →

Track INCY and 30,000+ stocks' live compliance status with Islamicly — 50% off with code ZAKAT50.Get Islamicly →